Lantheus Holdings, Inc.

Lantheus Holdings, Inc. develops and commercializes diagnostic imaging agents used in nuclear medicine, with a portfolio centered on PET radiodiagnostics, ultrasound contrast agents, and selected legacy SPECT products. The company’s business is built around products that help clinicians detect and characterize disease, especially in oncology, cardiology, and neurology, and it also earns royalties and milestone payments from licensed products.

61,1 %

15,2 %

+0,5 %

2.70

2.51

— Lantheus Holdings, Inc.
%
PET radiodiagnostics60% PET imaging agents used to detect and stage disease, including prostate cancer and amyloid imaging.
Ultrasound contrast agents20% Microbubble-based agents used to improve echocardiography image quality and cardiac assessment.
SPECT diagnostics10% Legacy single-photon imaging products used in nuclear medicine procedures and hospital workflows.
Licensed products and royalties5% Economics from licensed assets such as Flyrcado, including milestone and royalty payments.
Contract manufacturing and services5% Manufacturing services and related radiopharmaceutical production capabilities for third parties.

Lantheus sells primarily to hospitals, imaging centers, nuclear medicine departments, and physician practices that...

  • Hospitals and integrated health systemsprimary

    Buy imaging agents for routine and specialized diagnostic workflows across nuclear medicine and echocardiography.

  • Outpatient imaging centersprimary

    Purchase PET and ultrasound contrast products to support high-throughput diagnostic scans.

  • Cardiology practicessecondary

    Use DEFINITY to improve endocardial border definition and diagnostic confidence in echocardiograms.

  • Oncology and urology providersprimary

    Use PYLARIFY to detect PSMA-positive prostate cancer lesions and support treatment planning.

  • Neurology and memory care providerssecondary

    Use Neuraceq for amyloid PET imaging when evaluating patients for Alzheimer’s disease.

Lantheus is headquartered in Massachusetts and operates with offices in New Jersey, Canada, Germany, Switzerland,...

  • •Headquartered in Massachusetts, with a key production footprint in North Billerica
  • •U.S. market is central because most products are sold into American healthcare systems
  • •International offices in Canada, Germany, Switzerland, Sweden, and the UK support sales
  • •European presence matters for licensing, commercialization, and regulatory execution
  • •Canadian operations were part of the SPECT business sold to SHINE in 2026

Lantheus is narrowing its portfolio toward higher-growth radiopharmaceuticals and PET diagnostics after selling its...

01
Reposition the portfolio toward PET radiodiagnosticsshort-term

The SPECT sale simplifies the business and concentrates resources on higher-growth imaging categories.

02
Protect PYLARIFY’s commercial franchiseshort-term

PYLARIFY is a major revenue driver and faces reimbursement, manufacturing, and competition risks.

03
Expand through partnerships and licensingmedium-term

Licensing can extend reach without full internal commercialization costs.

04
Build the next pipeline of radiopharmaceutical assetsmedium-term

New products are needed to offset exclusivity expiry and sustain growth.

The company depends heavily on a small number of imaging products, especially PYLARIFY, so reimbursement changes,...

high

PYLARIFY commercial concentration

A substantial share of revenue depends on one product and its reimbursement/access profile.

Scope
PYLARIFY
Materiality
high
high

Competition and loss of exclusivity

Competitors already market or are developing alternative PET agents and ultrasound products.

Scope
PYLARIFY, DEFINITY, Neuraceq
Materiality
high
high

Manufacturing and supply chain disruption

Radiopharmaceutical production is time-sensitive and depends on specialized facilities and inputs.

Scope
PMFs, raw materials, logistics, radiopharmacist capacity
Materiality
high
high

Regulatory and reimbursement changes

Coverage, coding, and payment decisions directly affect adoption and net sales.

Scope
U.S. healthcare reimbursement
Materiality
high
medium

Cybersecurity and AI operational risk

Digital systems support research, manufacturing, and commercialization, creating attack and error exposure.

Scope
Enterprise IT and operational systems
Materiality
medium
Revenue recognition and rebate accruals
Can materially change reported revenue and receivables
Acquisition accounting
Affects goodwill, amortization, and operating expenses
Seasonality
Quarterly comparability and working capital swings
Asset retirement and facility assurance
Relevant to contingent obligations and facility-related estimates

Lantern Pharma Inc.

LTRN · Pharmaceutical Preparations

Pasithea Therapeutics Corp.

KTTAW · Pharmaceutical Preparations

LadRx Corp

Biological Products, (No Diagnostic Substances)

Actinium Pharmaceuticals, Inc.

ATNM · Pharmaceutical Preparations

Sensus Healthcare, Inc.

SRTS · Surgical & Medical Instruments & Apparatus

Assertio Holdings, Inc.

Pharmaceutical Preparations

: 28/04/2026